Estrogen receptor positive breast cancer identified by 95-gene classifier as at high risk for relapse shows better response to neoadjuvant chemotherapy

详细信息    查看全文

• 作者：Ryo Tsunashima ; Yasuto Naoi ; Kazuki Kishi ; Yosuke Baba ; Atsushi Shimomura ; Naomi Maruyama ; Takahiro Nakayama ; Kenzo Shimazu ; Seung Jin Kim ; Yasuhiro Tamaki ; Shinzaburo Noguchi
• 关键词：Breast cancer ; 95-Gene classifier ; Neoadjuvant chemotherapy ; Prognosis
• 刊名：Cancer Letters
• 出版年：2012
• 出版时间：1 November, 2012
• 年：2012
• 卷：324
• 期：1
• 页码：42-47
• 全文大小：589 K

文摘

A 95-gene classifier (95-GC) recently developed by us can predict the risk of relapse for ER-positive and node-negative breast cancer patients with high accuracy. This study investigated association of risk classification by 95-GC with response to neoadjuvant chemotherapy (NAC). Tumor biopsy samples obtained preoperatively from 72 patients with ER-positive breast cancer were classified by 95-GC into high-risk and low-risk for relapse. Pathological complete response (pCR) rate was numerically higher for high-risk (15.8 % ) than low-risk patients (8.8 % ) although the difference was not statistically significant. Pathological response evaluated in terms of the pathological partial response (pPR) rate (loss of tumor cells in more than two-thirds of the primary tumor) showed a significant association (P = 0.005) between the high-risk patients and a high pPR rate. Besides, external validation study using the public data base (GSE25066) showed that the pCR rate (16.4 % ) for high-risk patients (n = 128) was significantly (P = 0.003) higher than for low-risk patients (5.7 % ) (n = 159). These results demonstrate that the high-risk patients for relapse show a higher sensitivity to chemotherapy and thus are likely to benefit more from adjuvant chemotherapy.